{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:01:10Z","timestamp":1789084870963,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-039-032"],"award-info":[{"award-number":["NSTC 112-2314-B-039-032"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["NSTC 113-2314-B-039-054"],"award-info":[{"award-number":["NSTC 113-2314-B-039-054"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012544","name":"China Medical University","doi-asserted-by":"publisher","award":["CMU113-MF-64"],"award-info":[{"award-number":["CMU113-MF-64"]}],"id":[{"id":"10.13039\/501100012544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diabet.2025.101694","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:00:52Z","timestamp":1754431252000},"page":"101694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SGLT2 inhibitor and urothelial carcinoma incidence in type 2 diabetes patients"],"prefix":"10.1016","volume":"51","author":[{"given":"Yu-Chuan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hsiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hsun","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hua","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei-Ming","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Huei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Jen","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Shun","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laing-You","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Jung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2025.101694_bib0001","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.urolonc.2019.11.010","article-title":"PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy","volume":"38","author":"Yeh","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.diabet.2025.101694_bib0002","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jnci\/djp467","article-title":"Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk","volume":"102","author":"Lai","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.diabet.2025.101694_bib0003","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.eururo.2008.01.054","article-title":"Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients","volume":"54","author":"Li","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.diabet.2025.101694_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/719578","article-title":"A review on the relationship between SGLT2 inhibitors and cancer","volume":"2014","author":"Lin","year":"2014","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.diabet.2025.101694_bib0005","doi-asserted-by":"crossref","first-page":"e3784","DOI":"10.1002\/dmrr.3784","article-title":"Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: a real-world evidence study","volume":"40","author":"Sung","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabet.2025.101694_bib0006","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3390\/biomedicines11071867","article-title":"SGLT2 Inhibitors as potential anticancer agents","volume":"11","author":"Basak","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.diabet.2025.101694_bib0007","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1590\/s1677-5538.ibju.2018.0271","article-title":"Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications","volume":"45","author":"Kobayashi","year":"2019","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.diabet.2025.101694_bib0008","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1900\/RDS.2011.8.348","article-title":"SGLT-2 inhibitors in development for type 2 diabetes treatment","volume":"8","author":"Bhartia","year":"2011","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.diabet.2025.101694_bib0009","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/ecp.11.54","article-title":"Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus","volume":"4","author":"Gerich","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.diabet.2025.101694_bib0010","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101694_bib0011","first-page":"453","article-title":"SGLT-2 inhibitors and their potential in the treatment of diabetes","volume":"6","author":"Rosenwasser","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.diabet.2025.101694_bib0012","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/jcpt.12077","article-title":"The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors","volume":"38","author":"Cangoz","year":"2013","journal-title":"J Clin Pharma Ther"},{"key":"10.1016\/j.diabet.2025.101694_bib0013","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2025.101694_bib0014","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101694_bib0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jcph.1722","article-title":"SGLT2 inhibitors and bladder cancer: analysis of cases reported in the european pharmacovigilance database","volume":"61","author":"Garcia","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.diabet.2025.101694_bib0016","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/dom.13745","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: a meta-analysis of randomized controlled trials","volume":"21","author":"Dicembrini","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101694_bib0017","first-page":"157","article-title":"Accuracy of diabetes diagnosis in health insurance claims data in Taiwan","volume":"104","author":"Lin","year":"2005","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.diabet.2025.101694_bib0018","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101694_bib0019","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00592-020-01479-8","article-title":"Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials","volume":"57","author":"Dicembrini","year":"2020","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabet.2025.101694_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-022-01344-7","article-title":"Use of antihyperglycemic drugs and risk of cancer in patients with diabetes","volume":"25","author":"Sondergaard","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.diabet.2025.101694_bib0021","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.diabet.2025.101694_bib0022","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.diabet.2025.101694_bib0023","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.diabet.2025.101694_bib0024","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.diabet.2025.101694_bib0025","doi-asserted-by":"crossref","first-page":"e3797","DOI":"10.1002\/dmrr.3797","article-title":"SGLT2 inhibition and three urological cancers: up-to-date results","volume":"40","author":"Lin","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabet.2025.101694_bib0026","article-title":"Hyperglycemia, a neglected factor during cancer progression","author":"Duan","year":"2014","journal-title":"Biomed Res Int 2014"},{"key":"10.1016\/j.diabet.2025.101694_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121781","article-title":"Glycosylation in breast cancer progression and mammary development: molecular connections and malignant transformations","volume":"326","author":"Liang","year":"2023","journal-title":"Life Sci"},{"key":"10.1016\/j.diabet.2025.101694_bib0028","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fonc.2019.00380","article-title":"Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks","volume":"9","author":"Peixoto","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.diabet.2025.101694_bib0029","first-page":"4050","article-title":"Duration of diabetes mellitus and risk of kidney and bladder cancer: a longitudinal nationwide cohort study","volume":"12","author":"Choi","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.diabet.2025.101694_bib0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jdiacomp.2013.01.004","article-title":"Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis","volume":"27","author":"Bao","year":"2013","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabet.2025.101694_bib0031","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/1471-2407-13-310","article-title":"Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies","volume":"13","author":"Zhu","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.diabet.2025.101694_bib0032","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes care"},{"key":"10.1016\/j.diabet.2025.101694_bib0033","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pcd.2020.06.001","article-title":"Metformin and risk of cancer among patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.diabet.2025.101694_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110821","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway","volume":"132","author":"Zhou","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.diabet.2025.101694_bib0035","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.2337\/dc21-1917","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of bladder and renal cancer: scandinavian Cohort Study","volume":"45","author":"Ueda","year":"2022","journal-title":"Diabetes care"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:22:41Z","timestamp":1777609361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363625000886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1262363625000886"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101694","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitor and urothelial carcinoma incidence in type 2 diabetes patients","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101694"}}